Proteomic strategies and challenges in tumor metastasis research

被引:18
作者
Hudler, Petra [1 ]
Gorsic, Masa [1 ]
Komel, Radovan [1 ]
机构
[1] Univ Ljubljana, Med Ctr Mol Biol, Fac Med, Ljubljana 1000, Slovenia
关键词
Proteomics; Cancer; Metastases; Tumor biomarkers; Mass spectrometry; 2D-electrophoresis; Protein microarrays; CELL SIGNALING ANALYSIS; MASS-SPECTROMETRY; PLASMA-PROTEOME; OVARIAN-CANCER; 2-DIMENSIONAL ELECTROPHORESIS; HYDROGEL PARTICLES; GASTRIC-CANCER; SERUM; EXPRESSION; BIOMARKERS;
D O I
10.1007/s10585-010-9339-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The rapidly evolving field of proteomics offers new approaches to understanding the pathogenesis of cancer and metastatic disease. Although numerous tumor markers have been identified with different genomic methods in the past, most are either not specific or sensitive enough to be used in routine clinical setting. The rationale for proteomic profiling is based on the fact that proteins represent the dynamic state of the cells, reflecting pathophysiological changes in the disease more accurately than genomic and epigenetic alterations. Emerging proteomic techniques allow simultaneous assessment of a large number of proteins at one time. The study of protein profiles in complex systems, such as plasma, serum or tissues of cancer patients is likely to become valuable for monitoring the response of patients during treatment or for detecting recurrence of the disease.
引用
收藏
页码:441 / 451
页数:11
相关论文
共 93 条
[1]   Proteomic analysis of human prostate cancer [J].
Ahram, M ;
Best, CJM ;
Flaig, MJ ;
Gillespie, JW ;
Leiva, IM ;
Chuaqui, RF ;
Zhou, G ;
Shu, HJ ;
Duray, PH ;
Linehan, WM ;
Raffeld, M ;
Ornstein, DK ;
Zhao, YM ;
Petricoin, EF ;
Emmert-Buck, MR .
MOLECULAR CARCINOGENESIS, 2002, 33 (01) :9-15
[2]   Clinical cancer proteomics: Promises and pitfalls [J].
Alaiya, A ;
Al-Mohanna, M ;
Linder, S .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (04) :1213-1222
[3]  
American Cancer Society, TUM MARK
[4]  
[Anonymous], 2007, NCCN clinical practice guidelines in oncology: breast cancer
[5]   A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen [J].
Asara, John M. ;
Christofk, Heather R. ;
Freimark, Lisa M. ;
Cantley, Lewis C. .
PROTEOMICS, 2008, 8 (05) :994-999
[6]   Proteomics from the clinical perspective: many hopes and much debate [J].
Beretta, Laura .
NATURE METHODS, 2007, 4 (10) :785-786
[7]   Advances in functional protein microarray technology [J].
Bertone, P ;
Snyder, M .
FEBS JOURNAL, 2005, 272 (21) :5400-5411
[8]   Bioinformatics in proteomics [J].
Blueggel, M ;
Chamrad, D ;
Meyer, HE .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (01) :79-88
[9]   Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells [J].
Chen, Yet-Ran ;
Juan, Hsueh-Fen ;
Huang, Hsuan-Cheng ;
Huang, Hsin-Hung ;
Lee, Ya-Jung ;
Liao, Mei-Yueh ;
Tseng, Chien-Wei ;
Lin, Li-g Lin ;
Chen, Jeou-Yuan ;
Wang, Mei-Jung ;
Chen, Jenn-Han ;
Chen, Yu-Ju .
JOURNAL OF PROTEOME RESEARCH, 2006, 5 (10) :2727-2742
[10]   Contribution of oncoproteomics to cancer biomarker discovery [J].
Cho, William C. S. .
MOLECULAR CANCER, 2007, 6 (1)